FierceBiotech by Conor Hale, Apr 9, 2019 Concerto HealthAI has inked its second real-world data collaboration with a Big Pharma company in as many weeks, this time to help Pfizer select patients for its precision oncology development work. Concerto, a SymphonyAI company, aims to design more efficient clinical trials using prefabricated control arms and data […]
FiercePharma / by Eric Sagonowsky onMay 3, 2017 On the heels of highly anticipated cardiovascular outcomes data for PCSK9 med Repatha, Amgen has signed a money-back guarantee with Harvard Pilgrim. Through the first-of-its-kind contract, if a patient on Repatha has a heart attack or stroke, the drugmaker will provide a full refund. As the […]
by Amirah Al Idrus in FierceBiotech on Apr 19, 2017 Verily’s Project Baseline, which aims to better understand what it means to be healthy and how health transitions to disease, has launched in partnership with Duke University and Stanford University. The study will collect health data from 10,000 participants over four years. The study will […]
Pharmatimes Online. 15 May 2013 The pharmaceutical industry has now entered the Outcomes Era where compounds must supply convincing evidence of a new drug’s value, with proof of the best possible health outcomes and additional benefits if it is to achieve attractive price and reimbursement levels, says new research.As many as 60% of pharmaceutical executives […]